Nagelhout J J
College of Pharmacy, Wayne State University, Detroit, Michigan.
Nurs Clin North Am. 1991 Jun;26(2):401-15.
An increased understanding of the pathophysiologic changes underlying CHF, advanced monitoring technology, and a wider array of drug therapy have improved the prognosis of patients with this disorder. These advances allow for greater individualization of therapy, improve patient compliance, and lower the incidence of undesirable side effects. Of course, with the increase in complexity of treatment choices comes the need for more knowledgeable practitioners who can select the most appropriate therapeutic approach. All practitioners also must make every effort to educate the patients about their disease, treatments, and necessary lifestyle changes so that optimal benefits can be realized.